Akebia Therapeutics (STU:AX9) EBIT per Share : €-0.17 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics EBIT per Share?

Akebia Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was €-0.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.17.

During the past 3 years, the average EBIT per Share Growth Rate was 55.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 41.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Akebia Therapeutics's EBIT per Share or its related term are showing as below:

STU:AX9' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.6 Med: 10.5 Max: 55.2
Current: 55.2

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Akebia Therapeutics was 55.20% per year. The lowest was -63.60% per year. And the median was 10.50% per year.

STU:AX9's 3-Year EBIT Growth Rate is ranked better than
94.48% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs STU:AX9: 55.20

Akebia Therapeutics's EBIT for the three months ended in Mar. 2024 was €-14.2 Mil.

Akebia Therapeutics EBIT per Share Historical Data

The historical data trend for Akebia Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics EBIT per Share Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.18

-2.24

-1.41

-0.41

-0.22

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.13	-0.05	-0.07	0.01	-0.07

Akebia Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Akebia Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-42.084	/	187.465
=	-0.22

Akebia Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.248	/	204.955
=	-0.07

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.17

Akebia Therapeutics (STU:AX9) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Akebia Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines